Special Episode: HER2 Testing in Breast Cancer: Improving IHC Performance - podcast episode cover

Special Episode: HER2 Testing in Breast Cancer: Improving IHC Performance

Feb 28, 202254 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

This podcast will help pathologists gain deeper skills in improving HER2 IHC testing in patients with breast cancer. and includes the following topics:

  • Optimizing IHC scoring across the HER2 spectrum in patients with breast cancer
  • Guidelines for conducting IHC and ISH testing of HER2 in patients with breast cancer
  • Application through cases of patients with breast cancer along the lower spectrum of HER2 expression
  • Suggestions for effective coordination and collaboration among pathologists, oncologists, and other key members of the cancer care team

The activity offers 0.75 CME/CMLE credit.

Learning Objectives:

Upon completion of this activity, you should be able to:

  • Appropriately score HER2 levels via immunohistochemistry (IHC) in routine and complex breast cancer cases in accordance with guidelines
  • Describe the factors that may affect IHC performance across the HER2 spectrum
  • Utilize in situ hybridization (ISH) testing in breast cancer cases when appropriate in accordance with guidelines
  • Discuss ways to prepare laboratories and cancer centers for HER2-low breast cancer identification, tracking, and reporting

Faculty:

Aysegul A Sahin, MD
Director of Educational Operations
Department of Pathology, Division of Pathology/Lab Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Ali Brown, MD, FASCP
Chief Officer, Medical Quality
American Society for Clinical Pathology
Washington, DC

Erin Downs-Kelly, DO
Director, Breast Pathology
Cleveland Clinic
Cleveland, OH

The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Credit Designation Statement
The ASCP designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ASCP designates this enduring material for a maximum of 0.75 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time

Method of Participation
To complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided on-line.

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

For the best experience, listen in Metacast app for iOS or Android
Open in Metacast
Special Episode: HER2 Testing in Breast Cancer: Improving IHC Performance | Inside the Lab podcast - Listen or read transcript on Metacast